v3.26.1
GOODWILL AND OTHER INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill

The changes in the carrying amounts in Goodwill were as follows:
Dollars in millions
Balance at December 31, 2025
$21,754 
Currency translation and other adjustments(14)
Balance at March 31, 2026
$21,740 

Other Intangible Assets

Other intangible assets consisted of the following:
Estimated
Useful Lives		March 31, 2026December 31, 2025
Dollars in millions
Gross carrying amountsAccumulated amortizationOther intangible assets, net Gross carrying amountsAccumulated amortizationOther intangible assets, net
R&D technology
6 years
$1,980 $(688)$1,293 $1,980 $(605)$1,375 
Acquired marketed product rights
3 – 17 years
61,385 (52,000)9,384 61,385 (51,646)9,739 
Capitalized software
3 – 10 years
1,476 (1,099)377 1,453 (1,064)389 
IPRD7,190 — 7,190 7,600 — 7,600 
Total$72,031 $(53,786)$18,244 $72,418 $(53,315)$19,103 

Amortization expense of Other intangible assets was $472 million and $863 million during the three months ended March 31, 2026 and 2025, respectively.

During the three months ended March 31, 2026, $410 million of IPRD impairment charges were recorded in Research and development expense. The charges represent a partial write-down of a radiopharmaceutical asset driven by an indication realignment within our portfolio as well as a partial write-down of a separate oncology asset based on recent clinical results.